Skip to main content

Table 2 Antipsychotic, and non-antipsychotic medication taken by patients with SMI

From: A prospective study of monitoring practices for metabolic disease in antipsychotic-treated community psychiatric patients

Drug

n (%)

Antipsychotic (n = 90)

 

Yes

83 (92.2)

No

7 (7.8)

One antipsychotic

71 (78.8)

Combination antipsychotic

12 (13.3)

Typical or atypical agent (n = 71)

 

   Typical

16 (22.5)

Zuclopenthixol

2 (2.8)

Flupenthixol

5 (7.0)

Haloperidol

1 (1.4)

Fluphenazine

1 (1.4)

Pipothiazine

1 (1.4)

Sulpiride

4 (5.6)

Trifluoperazine

2 (2.8)

   Atypical

55 (77.5)

Amisulpiride

3 (4.2)

Clozapine

7 (9.9)

Olanzapine

29 (40.8)

Quetiapine

8 (11.3)

Risperidone

8 (11.3)

Non-antipsychotic psychotropic drugs (n = 90)

 

   Antidepressants

 

SSRI

29 (32.2)

SNRI

9 (10)

NaSSA

4 (4.4)

TCA

7 (7.8)

MAOI

3 (3.3)

   Mood Stabiliser

 

Valproate

16 (17.8)

Lamotrigine

8 (8.9)

Carbamazepine

1 (1.1)

Lithium

15 (16.7)

   Other

 

Gabapentin

2 (2.2)

Benzodiazepines

28 (31.1)

Tryptophan

2 (2.2)

Anticholinergic agent

15 (16.7)

Non-psychotropic drugs (n = 90)

 

Antihypertensive agent

13 (14.4)

Thyroxine

10 (11.1)

Hypoglycaemic agent

4 (4.4)